Hydrochlorothiazide/Tasosartan

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHydrochlorothiazide/Tasosartan
Drug Alias NameTasosartan and Hydrochlorothiazide氢氯噻嗪TasosartanHydrochlorothiazide and TasosartanTasosartan/Hydrochlorothiazide
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsThiazide-sensitive sodium-chloride cotransporter inhibitors
TargetsThiazide-sensitive sodium-chloride cotransporterAngiotensin II Receptor Type 1
Therapy Area/IndicationsHypertensionHeart Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes HydrochlorothiazideTasosartan
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsHypertensionHeart Failure

Other Information

ATC CodeN/A
Related LinksN/A